Takeda Pharmaceutical Co. executives hid the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Takeda officials failed to warn consumers and doctors adequately about the company’s research that linked Actos to bladder cancer, Robert Eglet, a lawyer for Delores Cipriano and Bertha Triana, both of whom developed the disease after taking the drug, told jurors yesterday in closing arguments in a Las Vegas trial.
